USPTO Examiner COUGHLIN MATTHEW P - Art Unit 1626

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18764298BIO-BASED EPOXY CHAIN EXTENDER AND PREPARATION METHOD THEREOFJuly 2024January 2025Allow720NoNo
18657122SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORSMay 2024July 2025Allow1410NoNo
18426035NITRIC OXIDE RELEASING PRODRUGS OF MDA AND MDMAJanuary 2024June 2025Allow1710YesNo
18402325CROWN ETHER CARBENES AND METHODS OF USEJanuary 2024January 2025Allow1310NoNo
18390071PROCESSES FOR THE PREPARATION OF FURAZANOBENZIMIDAZOLES AND CRYSTALLINE FORMS THEREOFDecember 2023June 2025Allow1710NoNo
18524339SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELSNovember 2023August 2024Allow900NoNo
18513752GLP-1 Receptor Agonists and Uses ThereofNovember 2023January 2025Abandon1410NoNo
183846984,5-BIS(4-BROMOPHENYL)-1-HEXYL-2-(3,4-DIMETHOXYPHENYL)-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUNDOctober 2023March 2024Allow510NoNo
183836834-(2,4,5-TRIS(4-CHLOROPHENYL)-1H-IMIDAZOL-1-YL)BUTANOIC ACID AS AN ANTIMICROBIAL COMPOUNDOctober 2023January 2024Allow200NoNo
183797244-NITRO-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)BENZIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDOctober 2023December 2023Allow200NoNo
184757495-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTSSeptember 2023February 2025Allow1710NoNo
18373241METHODS FOR CONVERTING CBD TO TETRAHYDROCANNABINOLSSeptember 2023November 2024Abandon1410NoNo
18242305CROWN ETHER AMINES AND METHODS OF USESeptember 2023August 2024Allow1110YesNo
18456819COMPOSITIONS AND METHODS FOR INHIBITING GROUP II INTRON RNAAugust 2023May 2025Allow2021NoNo
18448696QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTSAugust 2023August 2024Allow1200YesNo
18363585PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORSAugust 2023November 2024Allow1620NoNo
18228192METHODS AND COMPOSITIONS FOR TERPENOID SYNTHESISJuly 2023June 2024Allow1110YesNo
18226767PRODRUG COMPOUNDS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) AND METHODS OF SYNTHESIZING THE SAMEJuly 2023December 2024Abandon1620NoNo
18351472CRYSTALSJuly 2023April 2024Allow1000NoNo
18269109SYSTEM AND METHOD FOR PREPARING EPOXY CHLOROPROPANEJune 2023July 2024Allow1210NoNo
18320906USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSYMay 2023September 2023Allow300YesNo
18316579TETRACYCLIC COMPOUNDS AND USES THEREOFMay 2023August 2024Allow1510NoNo
18299442ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASESApril 2023December 2024Allow2021NoNo
18194155GLUCAGON-LIKE PEPTIDE1 RECEPTOR AGONISTSMarch 2023January 2025Abandon2120NoNo
18110416BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADEFebruary 2023February 2025Abandon2411NoNo
18161603USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEXJanuary 2023November 2024Allow2220YesNo
18158006COMPOUND OR SALT THEREOF, COMPOSITION, CHEMILUMINESCENCE METHOD, METHOD FOR MEASURING CHEMILUMINESCENCE SIGNAL, REAGENT, REAGENT KIT, AND METHOD FOR ASSAYING ANALYTEJanuary 2023February 2025Allow2421NoNo
18093773ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENTJanuary 2023June 2025Allow3000NoNo
18147189NITRIC OXIDE RELEASING PRODRUGS OF MDA AND MDMADecember 2022October 2023Allow1010YesNo
18066000Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereofDecember 2022May 2025Allow2910NoNo
18063331COMPOUND AND POLYMER COMPOUND CONTAINING THE COMPOUNDDecember 2022July 2024Allow1920YesNo
18073728APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOFDecember 2022February 2024Allow1410NoNo
18070408TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERSNovember 2022April 2024Abandon1610NoNo
17985415LIGANDS TO CEREBLON (CRBN)November 2022June 2024Allow1920YesNo
17982983SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELSNovember 2022August 2023Allow1000NoNo
179816951,2,4-Oxadiazole Derivatives as ImmunomodulatorsNovember 2022December 2023Allow1410NoNo
17981201CROWN ETHER CARBENES AND METHODS OF USENovember 2022October 2023Allow1210NoNo
17981162CROWN ETHER AMINES AND METHODS OF USENovember 2022June 2023Allow700NoNo
17922999CO-CRYSTAL OF KETOPROFEN, LYSINE AND GABAPENTIN, PHARMACEUTICAL COMPOSITIONS AND THEIR MEDICAL USENovember 2022May 2025Allow3100NoNo
17967599SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORSOctober 2022February 2024Allow1620YesNo
18046205ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOFOctober 2022April 2024Allow1810NoNo
17963823TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIESOctober 2022November 2024Allow2511NoNo
17950772METHODS AND COMPOSITIONS FOR TERPENOID TRICYCLOALKANE SYNTHESISSeptember 2022January 2025Allow2851NoNo
17946908Antibodies to Symmetrically Dimethylated Arginine Analytes and Use ThereofSeptember 2022April 2025Allow3111NoNo
17931773Tripartite Androgen Receptor Eliminators, Methods and Uses ThereofSeptember 2022March 2025Allow3031YesNo
17940287PRODRUGS OF RILUZOLE AND THEIR METHOD OF USESeptember 2022August 2024Allow2320NoNo
17905799COMPOUND PRODUCING METHOD, AND COMPOUNDSeptember 2022February 2023Allow500NoNo
17902618IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATIONSeptember 2022April 2024Allow2020NoNo
17820845CANNABIS SPECIES AS INDUSTRIAL CHEMICAL FEEDSTOCKSAugust 2022January 2025Abandon2941NoNo
17819089DERIVATIVES OF DOLASTATIN 10 AND AURISTATINSAugust 2022November 2023Abandon1510NoNo
17816349USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSYJuly 2022January 2023Allow510YesNo
17841570SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORSJune 2022November 2023Allow1710NoNo
17750220PYRROLIDINE DERIVATIVESMay 2022July 2025Allow3710YesNo
17743534PROCESS FOR PREPARING ESTERS OF N-ACYLATED AMINO ACIDS WITH ACID-LABILE KETO PROTECTIVE GROUP FUNCTIONSMay 2022November 2023Abandon1810NoNo
17744470CATIONIC ANTIMICROBIAL OLIGO-GUANIDINIUM DENDRIMERS AND COMPOSITIONSMay 2022December 2023Abandon1910NoNo
17732659Cannabidiol (CBD) as Chemical for Treating Aging-related Degenerative Diseases and Promoting Health AgingApril 2022February 2024Abandon2211NoNo
17713221GLYCOPYRROLATE SALTSApril 2022September 2023Allow1820NoNo
17701404PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORSMarch 2022May 2023Allow1410NoNo
17692113ELECTRONIC DEVICES USING ORGANIC SMALL MOLECULE SEMICONDUCTING COMPOUNDSMarch 2022January 2025Abandon3421NoNo
17679659OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITIONFebruary 2022January 2024Abandon2311NoNo
17587268NERVE DAMAGE PREVENTING AND NERVE PROTECTING COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND THEIR USEJanuary 2022February 2024Allow2521NoNo
17574820NLRP3 INFLAMMASOME INHIBITORSJanuary 2022March 2024Allow2610NoNo
17570420METHOD FOR PRODUCING FISETIN OR FISETIN DERIVATIVESJanuary 2022November 2022Allow1000NoNo
17566248ATYPICAL COUPLING METHOD FOR THE PREPARATION OF 1,2-DI(THIOPHEN-2-YL)ETHENE-1,2-DIOL COMPOUNDS VIA A CU(II) CATALYSTDecember 2021April 2023Allow1510NoNo
17564079COMPOSITIONS OF BIOLOGICALLY ACTIVE MENAQUINOL DERIVATIVES AND METHODS OF TREATMENTDecember 2021April 2024Allow2720NoNo
17623205NEUROKININ-1 ANTAGONISTDecember 2021May 2025Allow4110NoNo
175416825-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTSDecember 2021June 2023Allow1910NoNo
17536383PREPARING METHOD OF COMPOUNDS INCLUDING AMIDE GROUP FROM TERTIARY AMINENovember 2021May 2024Allow3021YesNo
175278331,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- DioxygenaseNovember 2021June 2023Abandon1910NoNo
17526742DERIVATIVES OF SULINDAC CAN PROTECT NORMAL CELLS AGAINST OXIDATIVE DAMAGENovember 2021July 2023Allow2020NoNo
17517166NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USENovember 2021December 2024Allow3710YesNo
17495447BIS(ACETAMIDOPHENYL) GUANIDINOPHENYLETHYLPHOSPHONATES FOR USE IN THE PREVENTION AND/OR TREATMENT OF PAR-RELATED DISEASESOctober 2021December 2022Allow1400NoNo
17492469METHOD FOR TREATING DENGUE VIRUS INFECTIONOctober 2021April 2025Allow4240YesNo
17448508INDUCTION OF ARTERIOGENESIS WITH AN NO (NITRIC OXIDE) DONORSeptember 2021December 2024Abandon3810NoNo
17476261Antibodies to Symmetrically Dimethylated Arginine Analytes and Use ThereofSeptember 2021August 2022Allow1121NoNo
17472016USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSYSeptember 2021November 2022Allow1420YesNo
17462155BIARYL COMPOSITIONS IN COMBINATION WITH TAMOXIFEN AND METHODS FOR MODULATING A KINASE CASCADEAugust 2021October 2024Abandon3701NoNo
17460922PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONSAugust 2021February 2025Abandon4110NoNo
17460061CRYSTALSAugust 2021March 2023Allow1910NoNo
17408458CANNABIS FARMING METHODSAugust 2021May 2025Abandon4431YesNo
17445057CYCLOPHANE-SUSTAINED HIGH PERFORMANCE PORPHYRINSAugust 2021May 2024Allow3321NoNo
17391202COMPOSITION CONTAINING AN ALK5 INHIBITOR, EW-7197August 2021August 2024Abandon3740NoNo
17381441Cannabinoid Compositions and Methods for Treating Joint Pain and InflammationJuly 2021August 2024Abandon3721NoNo
17424220METHODS FOR ENANTIOSELECTIVE PREPARATION OF CHIRAL TETRAARYLMETHANESJuly 2021March 2025Allow4420NoNo
17422587COMPOSITION FOR COMPETITIVE INHIBITION OF OREXIN RECEPTORSJuly 2021November 2024Abandon4010NoNo
17419930AN EFFICIENT AND ENVIRONMENT FRIENDLY PROCESS FOR CHLOROMETHYLATION OF SUBSTITUTED BENZENESJune 2021March 2022Allow800NoNo
17360315METHODS OF SYNTHESIZING ENANTIOPURE DEUTERIUM-ENRICHED PIOGLITAZONEJune 2021May 2023Allow2210NoNo
17359424TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERSJune 2021June 2024Allow3621NoNo
17356756COVALENT FUNCTIONALIZATION OF CARBON NANOTUBES GROWN ON A SURFACEJune 2021January 2024Abandon3111NoNo
17353567QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTSJune 2021July 2023Allow2511NoNo
17349998AI ASSISTED CYCLIC CARBONATE MONOMER SYNTHESISJune 2021August 2024Allow3821YesNo
173376152-(4-chloro-2,6-dimethyl-phenyl)propanedinitrileJune 2021February 2023Abandon2010NoNo
17328531METHODS OF SYNTHESIS FOR A THIOKETAL DIOLMay 2021January 2023Allow2020YesNo
17320286FARNESOID X RECEPTOR MODULATORSMay 2021December 2024Allow4421NoNo
17292249METHOD FOR PRODUCING CARBONATE DERIVATIVEMay 2021April 2025Allow4710YesNo
17307905TRICYCLIC P2-LIGAND CONTAINING POTENT HIV-PROTEASE INHIBITORS AGAINST HIV/AIDSMay 2021February 2022Allow910NoNo
17245235TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOFApril 2021August 2023Allow2820NoNo
17285785CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASEApril 2021January 2024Allow3331NoNo
17285443METHODS FOR EXTRACTION, PROCESSING, AND PURIFICATION OF A SELECTED FAMILY OF TARGET COMPOUNDS FROM CANNABISApril 2021September 2021Allow510NoNo
17217599SMALL MOLECULE IRE1-ALPHA INHIBITORSMarch 2021November 2022Abandon2010NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner COUGHLIN, MATTHEW P.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
9
Examiner Affirmed
4
(44.4%)
Examiner Reversed
5
(55.6%)
Reversal Percentile
81.0%
Higher than average

What This Means

With a 55.6% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
46
Allowed After Appeal Filing
12
(26.1%)
Not Allowed After Appeal Filing
34
(73.9%)
Filing Benefit Percentile
34.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 26.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner COUGHLIN, MATTHEW P - Prosecution Strategy Guide

Executive Summary

Examiner COUGHLIN, MATTHEW P works in Art Unit 1626 and has examined 1,279 patent applications in our dataset. With an allowance rate of 71.1%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 25 months.

Allowance Patterns

Examiner COUGHLIN, MATTHEW P's allowance rate of 71.1% places them in the 26% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by COUGHLIN, MATTHEW P receive 1.64 office actions before reaching final disposition. This places the examiner in the 44% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by COUGHLIN, MATTHEW P is 25 months. This places the examiner in the 64% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +14.3% benefit to allowance rate for applications examined by COUGHLIN, MATTHEW P. This interview benefit is in the 57% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 28.2% of applications are subsequently allowed. This success rate is in the 41% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 52.1% of cases where such amendments are filed. This entry rate is in the 73% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 71.0% of appeals filed. This is in the 53% percentile among all examiners. Of these withdrawals, 77.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 59.5% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 6.5% of allowed cases (in the 92% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.3% of allowed cases (in the 60% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.